HomeCompareBNOEF vs VIG

BNOEF vs VIG: Dividend Comparison 2026

BNOEF yields 33333.33% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNOEF wins by $8.428195308647591e+21M in total portfolio value
10 years
BNOEF
BNOEF
● Live price
33333.33%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.428195308647591e+21M
Annual income
$8,378,748,509,141,157,000,000,000,000.00
Full BNOEF calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — BNOEF vs VIG

📍 BNOEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNOEFVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNOEF + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNOEF pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNOEF
Annual income on $10K today (after 15% tax)
$2,833,333.33/yr
After 10yr DRIP, annual income (after tax)
$7,121,936,232,769,983,000,000,000,000.00/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, BNOEF beats the other by $7,121,936,232,769,983,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNOEF + VIG for your $10,000?

BNOEF: 50%VIG: 50%
100% VIG50/50100% BNOEF
Portfolio after 10yr
$4.2140976543237957e+21M
Annual income
$4,189,374,254,570,578,700,000,000,000.00/yr
Blended yield
99.41%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNOEF buys
0
VIG buys
0
No recent congressional trades found for BNOEF or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNOEFVIG
Forward yield33333.33%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.428195308647591e+21M$32.4K
Annual income after 10y$8,378,748,509,141,157,000,000,000,000.00$179.15
Total dividends collected$8.424943808765552e+21M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BNOEF vs VIG ($10,000, DRIP)

YearBNOEF PortfolioBNOEF Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$3,344,033$3,333,333.33$11,304$163.92+$3.33MBNOEF
2$1,045,333,048$1,041,754,932.50$12,759$166.33+$1045.32MBNOEF
3$305,463,295,767$304,344,789,404.97$14,382$168.52+$305463.28MBNOEF
4$83,443,192,327,233$83,116,346,600,762.75$16,192$170.52+$83443192.31MBNOEF
5$21,308,754,850,592,396$21,219,470,634,802,260.00$18,210$172.34+$21308754850.57MBNOEF
6$5,087,082,937,849,453,000$5,064,282,570,159,319,000.00$20,460$173.98+$5087082937849.43MBNOEF
7$1,135,355,897,925,379,400,000$1,129,912,719,181,880,500,000.00$22,968$175.48+$1135355897925379.50MBNOEF
8$236,895,694,937,506,160,000,000$235,680,864,126,726,020,000,000.00$25,763$176.83+$236895694937506176.00MBNOEF
9$46,211,962,155,546,610,000,000,000$45,958,483,761,963,480,000,000,000.00$28,878$178.05+$46211962155546607616.00MBNOEF
10$8,428,195,308,647,591,000,000,000,000$8,378,748,509,141,157,000,000,000,000.00$32,350$179.15+$8.428195308647591e+21MBNOEF

BNOEF vs VIG: Complete Analysis 2026

BNOEFStock

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Full BNOEF Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this BNOEF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNOEF vs SCHDBNOEF vs JEPIBNOEF vs OBNOEF vs KOBNOEF vs MAINBNOEF vs DGROBNOEF vs NOBLBNOEF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.